

IMPACT FACTOR 4.9

Indexed in: PubMed



an Open Access Journal by MDPI

Novel Therapeutics and Therapeutic Resistance in Hematological Malignancy

Guest Editors:

Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy

Dr. Giovanni Martinelli

Department of Hematology and Sciences Oncology, Institute of Haematology "L. and A. Seràgnoli" S. Orsola, University of Bologna, Bologna, Italy

Deadline for manuscript submissions:

closed (31 December 2023)

Message from the Guest Editors

Dear Colleagues,

The last few years have ushered in a new era of hematological malignancy research; the advent and approval of multiple targeted therapies and an improved understanding of patient immune systems have resulted in major progress in the development of immune therapies, including monoclonal antibodies with and without conjugated toxins (bacterial or chemical), bispecific T-cell engagers and DART antibodies, immune-checkpoint-based therapies, and CAR-T cell approaches.

At the same time, tumor biology has also seen recent advancements, leading to new combinations of drugs and novel therapies.

The numerous ongoing trials evaluating these therapies, with well-designed correlative interrogation of the immune system in patients treated in such trials, will further enhance our understanding of immune therapies with both single-agent and combination approaches.

This Topical Collection will focus on personalized medicine in hematology, the efficacy of novel therapeutics, and promising combination approaches for further improving patient treatment outcomes.

Dr. Claudio Cerchione Dr. Giovanni Martinelli Collection Editors



Specialsue









an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us